3 stories
Parkinson's disease coverage on Peptide News Digest sits at the intersection of GLP-1 secondary indications and traditional peptide neurology programs. Several GLP-1 agonist trials in Parkinson's (separate from the Alzheimer's EVOKE program) have shown disease-modifying signals in early-phase work.
The AAN 2026 living systematic review covered Parkinson's alongside Alzheimer's, multiple sclerosis, and stroke as part of the GLP-1 repositioning landscape. The mechanism work — GLP-1 receptors on dopaminergic neurons, neuroinflammation modulation — is suggestive but the Phase 3 data is still pending in PD specifically.
Stories here cover trial readouts and the registry data that contextualize them. See #neurology and #neurodegeneration for adjacent threads.
A comprehensive NeurologyLive review details emerging evidence for GLP-1 receptor agonists across neurological diseases including Alzheimer's, Parkinson's, multiple sclerosis, and stroke. Despite setbacks in the Phase 3 EVOKE Alzheimer's trial, ongoing trials like LIGHT-MCI and OxSENSE continue to explore neurobiological mechanisms beyond metabolic effects.
Comprehensive review examining GLP-1 receptor agonists for neurological conditions. A recent NEJM trial showed GLP-1 treatment resulted in less motor disability progression at 12 months.
A comprehensive NeurologyLive review examines evidence for repositioning GLP-1 drugs across neurological conditions. Exenatide and lixisenatide show motor benefits in Parkinson's disease, while GLP-1 agonists reduced intracranial pressure and migraine days in idiopathic intracranial hypertension. The semaglutide EVOKE trials in Alzheimer's failed clinically despite modest biomarker improvements.